HS

ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is Investigating Acelyrin, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Samstag, Mai 18, 2024
HS, SLRN, IPO, Telephone, Complaint, Defendant, P.C

NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Acelyrin, Inc. (NASDAQ: SLRN) on behalf of long-term stockholders following a class action complaint that was filed against Acelyrin on November 15, 2023 with a Class Period from May 4, 2023 to September 11, 2023.

Key Points: 
  • NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Acelyrin, Inc. (NASDAQ: SLRN) on behalf of long-term stockholders following a class action complaint that was filed against Acelyrin on November 15, 2023 with a Class Period from May 4, 2023 to September 11, 2023.
  • Our investigation concerns whether the board of directors of Acelyrin have breached their fiduciary duties to the company.
  • According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • There is no cost or obligation to you.

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

Retrieved on: 
Donnerstag, Mai 16, 2024
IL-17A, Patient, University of Miami, Food, European Medicines Agency, Clinical trial, University, Depression, FDA, Associate professor, Moonlake, Single-domain antibody, Inflammation, MIRA, EMA, Tissue, Scar, HS, Pain, VELA, MAS, Pharmaceutical industry

Sonelokimab is designed to directly target sites of inflammation by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers and to penetrate difficult-to-reach inflamed tissues.

Key Points: 
  • Sonelokimab is designed to directly target sites of inflammation by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers and to penetrate difficult-to-reach inflamed tissues.
  • Following the positive results from the landmark Phase 2 MIRA trial, the Phase 3 VELA program is expected to enroll 800 patients across VELA-1 and VELA-2.
  • The Phase 3 program will use a protocol design consistent with the Phase 2 MIRA trial, which identified the optimal dose of sonelokimab for HS.
  • The topline primary endpoint readout (week 16) from the VELA program is expected as of mid-2025.

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

Retrieved on: 
Dienstag, Mai 7, 2024
Komodo, Psoriatic arthritis, VELA, FDA, American Academy, Porokeratosis, Psoriasis, HS, Skin, Rheumatology, MDA, Research, Partnership, Conference, PPP, MIRA, Joint, Bimekizumab, Patient, EMA, AAD, Inflammation, PASI, Moonlake, Dermatology, ARGO, Pharmaceutical industry

Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.

Key Points: 
  • Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.
  • Research and development expenses for the quarter ended March 31, 2024, were $13.0 million, compared to $8.1 million in the previous quarter.
  • The increase was primarily due to expenses incurred to initiate the new clinical trials.
  • General and administrative expenses for the quarter ended March 31, 2024 were $6.8 million, similar to the $6.9 million incurred in the previous quarter.

Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
Donnerstag, Mai 9, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Ulcerative colitis, Systemic scleroderma, Alopecia areata, HS, Research and development, Administration, Patient, TSLP, Record, Inflammation, Senior, Atopic dermatitis, Asthma, Autoimmunity, G&A, Chronic obstructive pulmonary disease, Pharmaceutical industry

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its first quarter 2024 financial results, and recent business highlights.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its first quarter 2024 financial results, and recent business highlights.
  • "Our recent financial and business highlights demonstrate how we continue to strengthen the company for future success.
  • The private placement by leading life sciences investors emphasizes the confidence in our pipeline of novel, dual-pathway antibodies for autoimmune and inflammatory diseases,” stated Robert Lisicki, CEO of Zura Bio.
  • Zura Bio anticipates that with the recent private placement factored in, its cash and cash equivalents are sufficient to fund planned operations through 2027.

Kharon Data and Technology Selected by U.S. Department of the Treasury

Retrieved on: 
Dienstag, Mai 7, 2024
Public sector, Harmonized System, Financial Crimes Enforcement Network, Corruption, Risk, HS, Treasury, NLP, Department of the Treasury, Natural language processing, Risk management, KYC, Terrorism, Private sector, Organization, Cryptocurrency

WASHINGTON, May 7, 2024 /PRNewswire/ -- Kharon announces the signing of a contract with the U.S. Department of the Treasury. Through this engagement, officials within the Treasury Department will gain access to Kharon's global risk analytics platform. Kharon's insights and analytic tools are used by leading financial institutions, companies, and governments to address global security threats, and to support risk management in connection with KYC, transaction screening, sanctions evasion, investigations, and trade controls.

Key Points: 
  • WASHINGTON, May 7, 2024 /PRNewswire/ -- Kharon announces the signing of a contract with the U.S. Department of the Treasury.
  • Through this engagement, officials within the Treasury Department will gain access to Kharon's global risk analytics platform.
  • Alongside a recent award with the U.S. Customers and Border Protection, this engagement with the Treasury Department expands the U.S. Government's access to Kharon insights, data analytics, and investigative workflow tools for critical public sector security objectives.
  • We are proud to support the U.S. Department of the Treasury in its critical mission."

Kharon Data and Technology Selected by U.S. Department of the Treasury

Retrieved on: 
Dienstag, Mai 7, 2024
Public sector, Harmonized System, Financial Crimes Enforcement Network, Corruption, Risk, HS, Treasury, NLP, Department of the Treasury, Natural language processing, Risk management, KYC, Terrorism, Private sector, Organization, Cryptocurrency

WASHINGTON, May 7, 2024 /PRNewswire/ -- Kharon announces the signing of a contract with the U.S. Department of the Treasury. Through this engagement, officials within the Treasury Department will gain access to Kharon's global risk analytics platform. Kharon's insights and analytic tools are used by leading financial institutions, companies, and governments to address global security threats, and to support risk management in connection with KYC, transaction screening, sanctions evasion, investigations, and trade controls.

Key Points: 
  • WASHINGTON, May 7, 2024 /PRNewswire/ -- Kharon announces the signing of a contract with the U.S. Department of the Treasury.
  • Through this engagement, officials within the Treasury Department will gain access to Kharon's global risk analytics platform.
  • Alongside a recent award with the U.S. Customers and Border Protection, this engagement with the Treasury Department expands the U.S. Government's access to Kharon insights, data analytics, and investigative workflow tools for critical public sector security objectives.
  • We are proud to support the U.S. Department of the Treasury in its critical mission."

Tariffy Empowers Customs Brokers and Companies to Take Control of International Trade Compliance with AI

Retrieved on: 
Mittwoch, Mai 1, 2024
Multimedia, HTS, Harmonized System, Internet, Chocolate, Language, CIQ, ChatGPT, TARIC, HS, Online shopping

TALLINN, Estonia, May 1, 2024 /PRNewswire-PRWeb/ -- Businesses shipping goods internationally must follow a myriad of policies to ensure continued compliance with international trade policies. And to remain in compliance, customs brokers and companies spend a lot of time and energy to get the job done. One of these time-consuming processes is finding and using the correct Harmonized System codes (HS codes) to classify their shipments. But identifying the correct codes can be time-consuming, expensive, and cumbersome—until now, thanks to Tariffy.

Key Points: 
  • And to remain in compliance, customs brokers and companies spend a lot of time and energy to get the job done.
  • Think of Tariffy as ChatGPT's cousin, built specifically for the international trade and shipping industry.
  • Tariffy is an AI-powered assistant specifically built to tackle the headache-inducing world of HS codes in international trade.
  • "Think of Tariffy as ChatGPT's cousin, built specifically for the international trade and shipping industry," said Arnaud Granal, founder of Tariffy.

Jinpeng Group Presents "Jinpeng to World" to the World at the 135th Spring Canton Fair

Retrieved on: 
Donnerstag, April 18, 2024
Sale, HS, 134th, Woman, DLS, Exclaim!, Canton Fair, XY

Xuzhou, China--(Newsfile Corp. - April 18, 2024) - The 135th Canton Fair opened on April 15, with a total exhibition area of 1.55 million square meters.

Key Points: 
  • Xuzhou, China--(Newsfile Corp. - April 18, 2024) - The 135th Canton Fair opened on April 15, with a total exhibition area of 1.55 million square meters.
  • Jinpeng Group was invited to participate in the first phase focusing on "advanced manufacturing" and showed the world the new Jinpeng "smart" manufacturing in Hall 8.1 and Hall 13.1.
  • This Jinpeng booth received a total of nearly 10,000 overseas buyers from the Philippines, Brazil, Denmark, France, Germany, Italy, Turkey, Russia and other countries and regions.
  • The main product of the Spring Canton Fair, the product was unanimously recognized by the vast number of overseas buyers as soon as it was exhibited.

AGBA Stands Firm: The AGBA-Triller Merger is Value-Enhancing to All Stakeholders

Retrieved on: 
Donnerstag, April 25, 2024
Triller, Fintech, Social media, HS, AI

AGBA also has become aware of a similar press release issued by Halper Sadeh LLC (“HS”) on April 22, 2024.

Key Points: 
  • AGBA also has become aware of a similar press release issued by Halper Sadeh LLC (“HS”) on April 22, 2024.
  • AGBA believes that the proposed merger with Triller Corp will create significant value for all shareholders.
  • Given the rapidly changing landscape in the social media industry, AGBA is confident that Triller is well-positioned to capitalize on the unprecedented opportunities.
  • The proposed merger represents a unique combination of social media and content, as well as fintech and healthtech, leveraging the AI capabilities of the combined group.

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions 

Retrieved on: 
Mittwoch, April 10, 2024
Komodo, Psoriatic arthritis, Arthropathy, Holocene, HS, Skin, Hidradenitis suppurativa, Partnership, Research, Literature, Entrepreneurship, Disease, Steroid, Patient, Inflammation, Marketing, Moonlake, Prevalence, Pharmaceutical industry

San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.

Key Points: 
  • San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.
  • Through this multiyear technology partnership, MoonLake will utilize Komodo’s Healthcare Map and platform technologies to enable data-driven decision making across its clinical operations, medical, marketing, and market access teams.
  • Komodo’s data and technology applications will support MoonLake’s in-depth market research, clinical trial site selection, go-to-market strategies, and patient journey mapping – all aimed at accelerating the development of new treatment options and improving outcomes for patients with inflammatory skin and joint diseases.
  • Tino Anthamatten, VP Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, commented: “We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors.